

Appendix D.

Table S2-1. ACR20, ACR50 and ACR70 responses according to ADA status at week 30

Treatment	n	N	(%)	Estimate [1]	Treatment difference estimate [2]	95% CI of treatment difference
ADA positive						
ACR20 CT-P13 3 mg/kg	79	122	64.8	0.65	0.01	(-0.11, 0.13)
INX 3 mg/kg	78	121	64.5	0.64	.	
Goodness-of-fit test (p-value 0.986 [3])	
ACR50 CT-P13 3 mg/kg	36	122	29.5	0.29	-0.04	(-0.16, 0.08)
INX 3 mg/kg	41	121	33.9	0.34	.	
Goodness-of-fit test (p-value 0.984 [3])	
ACR70 CT-P13 3 mg/kg	9	122	7.4	0.07	-0.06	(-0.13, 0.02)
INX 3 mg/kg	16	121	13.2	0.13	.	
Goodness-of-fit test (p-value 0.850 [3])	
ADA negative						
ACR20 CT-P13 3 mg/kg	103	126	81.7	0.82	0.06	(-0.04, 0.16)
INX 3 mg/kg	97	129	75.2	0.75	.	
Goodness-of-fit test (p-value 0.769 [3])	
ACR50 CT-P13 3 mg/kg	69	126	54.8	0.54	0.07	(-0.06, 0.19)
INX 3 mg/kg	61	129	47.3	0.48	.	
Goodness-of-fit test (p-value 0.960 [3])	

Treatment	n	N	(%)	Estimate [1]	Treatment difference estimate [2]	95% CI of treatment difference
ACR70 CT-P13 3 mg/kg	41	126	32.5	0.33	0.10	(-0.01, 0.21)
INX 3 mg/kg	29	129	22.5	0.22	.	
Goodness-of-fit test (p-value 0.996 [3])	

Note: N = the number of subjects with an assessment. n = the number of subjects with the event. (%)= n/N*100.

[1] Estimates of proportions are calculated using a logistic regression model with treatment as a fixed effect, and region and CRP category as covariates.

[2] The estimate of treatment difference of proportions (CT-P13 — INX) and corresponding 95% confidence interval were estimated from the logistic regression results using the Delta method. This method assumes independence between treatment groups.

[3] P-value is calculated using the Hosmer-Lemeshow test for the goodness-of-fit of the logistic regression model. The test is significant at the 5% level.

Table S2-2. EULAR responses (moderate and good) according to ADA status at week 30

Parameter	Treatment	n	N	(%)	Relative Risk Estimate	95% CI of Relative Risk
ADA positive						
EULAR(CRP)	CT-P13 3 mg/kg	97	122	79.51	0.96	(0.85, 1.09)
	INX 3 mg/kg	99	120	82.50	.	
EULAR(ESR)	CT-P13 3 mg/kg	94	122	77.05	1.03	(0.89, 1.18)
	INX 3 mg/kg	90	120	75.00	.	
ADA negative						
EULAR(CRP)	CT-P13 3 mg/kg	114	124	91.94	1.01	(0.93, 1.08)
	INX 3 mg/kg	117	128	91.41	.	
EULAR(ESR)	CT-P13 3 mg/kg	113	123	91.87	1.03	(0.95, 1.12)
	INX 3 mg/kg	114	128	89.06	.	

Note: The estimate of treatment difference of proportions (CT-P13 – INX) and corresponding 95% confidence interval were estimated from the logistic regression results using the Delta method. This method assumes independence between treatment groups. A relative risk (RR) of 1 indicates 'no difference' in risk between treatment groups. A RR of >1 indicates the EULAR response is more likely to occur in the CT-P13 group than in the INX group. A RR of <1 indicates the EULAR response is less likely to occur in the CT-P13 group than in the INX group. N = the number of subjects with an assessment. n = the number of subjects with the event. (%) = n/N*100.

Table S2-3. DAS28 according to ADA status at week 30

Parameter	Treatment	n	Adjusted mean	(SE)	Estimate of treatment difference	95% CI of treatment difference
ADA positive						
DAS28(CRP)	CT-P13 3 mg/kg	122	-1.82	(0.109)	0.11	(-0.19, 0.42)
	INX 3 mg/kg	120	-1.93	(0.110)	.	
DAS28(ESR)	CT-P13 3 mg/kg	122	-2.02	(0.115)	0.07	(-0.25, 0.39)
	INX 3 mg/kg	120	-2.09	(0.115)	.	
ADA negative						
DAS28(CRP)	CT-P13 3 mg/kg	124	-2.61	(0.108)	-0.21	(-0.51, 0.08)
	INX 3 mg/kg	128	-2.40	(0.107)	.	
DAS28(ESR)	CT-P13 3 mg/kg	123	-2.83	(0.114)	-0.27	(-0.58, 0.05)
	INX 3 mg/kg	128	-2.57	(0.114)	.	

Note: Analysis of covariance (ANCOVA) model with DAS28 as the response, treatment as a fixed effect, and baseline DAS28, region and CRP category as covariates. Adjusted least squares means and standard error, estimate of treatment difference (CT-P13 — INX) and 95 Confidence Interval calculated from the ANCOVA model. A treatment difference >0 implies that a subject treated with CT-P13 has on average a higher increase in post-baseline DAS28 at the scheduled visit in comparison to a INX-treated subject.